Form 8-K - Current report:
SEC Accession No. 0001764013-25-000007
Filing Date
2025-01-13
Accepted
2025-01-13 08:07:00
Documents
16
Period of Report
2025-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20250113.htm   iXBRL 8-K 38370
2 EX-10.1 exhibit10120250113.htm EX-10.1 295579
3 EX-10.2 exhibit10220250113.htm EX-10.2 200077
4 EX-99.1 exhibit99120250113.htm EX-99.1 7795
  Complete submission text file 0001764013-25-000007.txt   755610

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20250113.xsd EX-101.SCH 1779
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20250113_lab.xml EX-101.LAB 21629
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20250113_pre.xml EX-101.PRE 12506
18 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20250113_htm.xml XML 2712
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 25524913
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)